

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2025 Company Presentations
All items marked with an * are mandatory to complete
The maximum number of words for this abstract is 400
Please be sure to complete the following:

1E Therapeutics Ltd * www.1etx.com *

Gur Roshwalb, MD

Select a CATEGORY: Biotech/Pharma *
(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below *
(Delete sessions you are not selecting)

- Redefining the fight against Cancer: New Targets and Novel Therapeutic Modalities

You may delete the section instructions, leaving only the bolded bullet title
Answers below should not exceed 60 words per question:

- Executive Summary – 1E Therapeutics is advancing a novel platform for RNA interference focusing on allele specific knockdown
- Core Technology – This novel mode of RNA interference is single base pair specific in its targeting capabilities allowing for allele and isoform specific knockdown
- Product Profile/Pipeline Company is preclinical focusing on targets in hematology, immunology and neurodegeneration. We are targeting opening INDs in 2027 and clinical POC in 2028.
- Business Strategy Briefly – by developing new therapies for our lead indications.
- What's Next? We are focusing on lead optimization, to be followed by in vivo POC and then pre-clinical toxicology studies.